By deploying advanced computational methods and unbiased screening directly in NHP's - we're mapping the future of delivery for genetic medicines. Designed to accurately target tissues and reduce unwanted interactions, our technology aims to minimize the risks of immunogenicity and toxicity, delivering the payload exactly where it's needed.
By developing more potent AAVs, our candidates are being designed to provide improved efficacy at low doses, potentially improving costs, manufacturing efficiency and patient safety.
Latus reduces aav doses via direct routes of administration (RoA) and engineering capsids with disease-specific tropism
Uniquely competitive offering to advance AAV therapeutics from ultra-rare to common disease indications
